AGTC Genomics

07/08/2026

𝗙𝗿𝗼𝗺 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝘁𝗼 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗣𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻: 𝗕𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮’𝘀 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻-𝗛𝗲𝗮𝗹𝘁𝗵 𝗘𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺

The future of healthcare is not only about treating disease — it is increasingly about predicting risk, preventing disease and personalising intervention earlier.

As part of AGTC Genomics’ ongoing series of Continuing Medical Education (CME) and professional awareness programmes with leading healthcare centres, our Chief Dietitian, Ms Samantha Wong, recently shared how precision nutrition, nutrigenomics, nutriepigenomics and gut microbiome science are reshaping the way we think about preventive health.

𝗪𝗵𝘆 𝗱𝗼𝗲𝘀 𝘁𝗵𝗶𝘀 𝗺𝗮𝘁𝘁𝗲𝗿?

The same diet does not produce the same outcome for everyone.

Our genetic differences can influence how we metabolise and respond to nutrients. At the same time, nutrition and lifestyle may influence gene regulation through epigenetic mechanisms, while the gut microbiome plays an increasingly recognised role in metabolism, immunity and overall health.

By integrating:

• Nutrigenomics — how genes influence our response to nutrition
• Nutriepigenomics — how nutrition and lifestyle may influence gene regulation
• Gut microbiome profiling — understanding the microbial ecosystem that contributes to health
• Clinical and nutritional assessment — translating complex biological data into meaningful action

we can move closer towards a more personalised, evidence-informed approach to prevention and long-term health management.

Importantly, advanced molecular testing should not replace clinical judgement. Its true value comes from combining genomics, microbiome and other biological information with professional healthcare expertise.

At AGTC Genomics, we believe education is just as important as technology.

Through our ongoing CME engagements with healthcare professionals and leading healthcare institutions, we aim to help build the knowledge and multidisciplinary capabilities required to translate emerging science into real-world preventive healthcare.

The next frontier of precision medicine is not simply treating disease better. It is understanding risk earlier, intervening sooner and helping people stay healthier for longer.

AGTC Genomics is strengthening its commitment to building Malaysia’s preventive and precision-health ecosystem through a series of Continuing Medical Education (CME), professional training and awareness programmes with leading healthcare centres, focusing on the emerging roles of preventive medici...

05/08/2026

The Cancer Test Trusted by Oncologists Globally

Cancer treatment decisions cannot wait. AGTC Genomics delivers fast turnaround times with CAP-accredited quality, helping oncologists act sooner with greater confidence.

05/08/2026

𝗬𝗼𝘂 𝗞𝗻𝗼𝘄 𝗬𝗼𝘂𝗿 𝗕𝗶𝗿𝘁𝗵𝗱𝗮𝘆—𝗕𝘂𝘁 𝗛𝗼𝘄 𝗢𝗹𝗱 𝗜𝘀 𝗬𝗼𝘂𝗿 𝗕𝗼𝗱𝘆? 🧬

Two people may be the same age on paper, yet their bodies can be aging at different rates.

Your chronological age is the number of years you have lived. Your biological age is an estimate of how your cells and body systems are aging from within.

AGTC Genomics’ Epigenetic Biological Age Test uses advanced epigenomics to support personalized health, longevity and preventive care.

𝗪𝗵𝗮𝘁 𝗱𝗼𝗲𝘀 𝘁𝗵𝗲 𝘁𝗲𝘀𝘁 𝗺𝗲𝗮𝘀𝘂𝗿𝗲?

The test studies DNA methylation—small chemical markers attached to DNA that help regulate how genes are used. These patterns naturally change as we age and may also reflect the combined influence of lifestyle, environmental exposures and health.

The science behind this approach is well established. In 2013, Professor Steve Horvath demonstrated that specific DNA methylation patterns could estimate age across many human tissues and cell types, creating one of the best-known “epigenetic clocks.”

𝗪𝗵𝘆 𝗶𝘀 𝗸𝗻𝗼𝘄𝗶𝗻𝗴 𝘆𝗼𝘂𝗿 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗮𝗴𝗲 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁?

Research has found that some people have an epigenetic age that is younger or older than expected for their chronological age. Faster epigenetic aging has been associated with poorer health outcomes and a higher risk of age-related decline.

Studies involving thousands of participants have shown that advanced epigenetic clocks can provide information associated with healthspan, physical functioning, cardiovascular disease, cancer and mortality risk beyond chronological age alone.

The AGTC Genomics report compares your biological age with your chronological age and provides insights across key body systems. It can highlight areas of strength and areas that may deserve greater attention.

𝗬𝗼𝘂𝗿 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗮𝗴𝗲 𝗶𝘀 𝗻𝗼𝘁 𝗻𝗲𝗰𝗲𝘀𝘀𝗮𝗿𝗶𝗹𝘆 𝗳𝗶𝘅𝗲𝗱

Research has linked healthier dietary patterns, physical activity and other lifestyle factors with more favourable epigenetic-aging profiles.

More recently, a three-year clinical trial involving 777 older adults found that certain interventions produced small but measurable changes in selected DNA methylation clocks. This suggests that epigenetic aging markers may be useful for monitoring changes over time.

Understanding your biological age may help you:

✅ Identify possible signs of accelerated aging earlier
✅ Make more informed lifestyle and preventive-health decisions
✅ Personalize nutrition, exercise, sleep and stress-management strategies
✅ Monitor how your biological aging profile changes over time
✅ Start meaningful conversations with qualified healthcare professionals

Age is more than a number. Understand how your body is aging—and take proactive steps towards a healthier future.

Biological age is a molecular health indicator, not a diagnosis or a prediction of exactly how long someone will live. Results should be interpreted together with medical history, clinical assessments and professional advice.

𝗦𝗲𝗹𝗲𝗰𝘁𝗲𝗱 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗿𝗲𝗳𝗲𝗿𝗲𝗻𝗰𝗲𝘀

1) Wyss-Coray, T. and Topol, E.J., 2026. Biological aging clocks in health and disease. Nature Medicine, pp.1-12.

2) Moqri, M., Poganik, J.R., Horvath, S. and Gladyshev, V.N., 2025. What makes biological age epigenetic clocks tick. Nature Aging, 5(3), pp.335-336.

3) Conole, E.L., Robertson, J.A., Smith, H.M., Cox, S.R. and Marioni, R.E., 2025. Epigenetic clocks and DNA methylation biomarkers of brain health and disease. Nature Reviews Neurology, 21(8), pp.411-421.

04/08/2026

𝗙𝗿𝗼𝗺 𝗟𝗮𝗯 𝘁𝗼 𝗟𝗶𝘃𝗲𝘀: 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗘𝗮𝗿𝗹𝘆 𝗖𝗮𝗻𝗰𝗲𝗿 𝗮𝗻𝗱 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝘂𝘀 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗧𝗵𝗿𝗼𝘂𝗴𝗵 𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮𝗻 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻

AGTC Genomics was honoured to participate in the One-Day International Symposium on “Biomarkers in Early Disease Detection and Vaccine Development: A Transformative Journey in Modern Medicine,” organised by the Department of Physiology, Faculty of Medicine, Universiti Malaya.

During the industry briefing, Professor Dr Chee Onn Leong, Founder and CEO of AGTC Genomics, shared our recent success in developing and commercialising Malaysia’s first locally developed Multi-Cancer Early Detection test, alongside advances in clinical shotgun metagenomics through collaboration with Universiti Malaya and Universiti Malaya Medical Centre.

Early detection can fundamentally change the course of disease. Identifying cancer before symptoms appear may create opportunities for earlier intervention, less complex treatment and better patient outcomes. Similarly, clinical shotgun metagenomics can support the broad detection of bacteria, viruses, fungi and other microorganisms, particularly in complex cases where conventional diagnostic methods may not identify the cause of infection.

The symposium also reinforced an important message: scientific discovery creates its greatest impact when academia, healthcare institutions and industry work together. Academic expertise drives discovery, clinicians ensure relevance to real patient needs, and industry provides the development, validation, quality and commercialisation capabilities required to bring innovation into clinical practice. This shared mission was central to the symposium’s focus on accelerating biomarker discovery, validation and clinical adoption.

It was a privilege to join an outstanding group of speakers:

Professor Dr Bhaskar Saha, HIV Research Laboratory, JSPS GHMC, India
Professor Dr Sazaly Bin Abu Bakar, Universiti Malaya
Professor Qasim Ayub, Monash University Malaysia
Professor Naguib Salleh, Universiti Malaya
Professor Dr Mukhri Bin Hamdan, Universiti Malaya
Dr Krishnamurithy Genasan, Universiti Malaya
Dr Sabyasachi Das, Universiti Malaya
Professor Dr Chee Onn Leong, AGTC Genomics, Industry Partner

Our appreciation also goes to Professor Dato’ Dr Yang Faridah Abdul Aziz, Dean of the Faculty of Medicine, Universiti Malaya, for the welcome address, and to the organising committee for creating a multidisciplinary platform connecting researchers, clinicians, academicians and industry leaders.

Malaysia has the scientific talent and clinical expertise to develop globally relevant precision medicine technologies. Strong academia–industry collaboration will be essential to translate these capabilities into accessible solutions that improve disease prevention, diagnosis and patient care.

https://www.agtcgenomics.com/post/malaysia-s-genomics-breakthrough-agtc-genomics-brings-earlier-cancer-and-infection-detection-into-c

31/07/2026

𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮’𝘀 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗙𝘂𝘁𝘂𝗿𝗲

How can Malaysia use digital health and precision medicine to make healthcare more equitable, preventive and accessible?

AGTC Genomics was honoured to contribute to the Academy of Sciences Malaysia’s Mission-Oriented Initiative on Digital Healthcare Stakeholder Engagement.

As an elected committee member, Professor Dr Chee-Onn Leong FASc, Founder and CEO of AGTC Genomics, shared perspectives on how genomics, artificial intelligence, clinical data and digital platforms can work together to address healthcare disparities and improve disease prevention, early detection and long-term health management.

Digital healthcare should not be measured only by technological sophistication. Its real impact lies in whether it enables more people to receive earlier, more accurate and more appropriate care.

Malaysia has the scientific talent, healthcare expertise and technological capabilities to build an inclusive, trusted and future-ready digital healthcare ecosystem. Strong collaboration across government, healthcare, academia and industry will be essential to turn this national ambition into measurable benefits for patients and communities.

AGTC Genomics remains committed to supporting Malaysia’s transition from reactive treatment towards prevention, precision medicine and proactive health management.

AGTC Genomics Contributes to Malaysia’s National Digital Healthcare Mission

31/07/2026

𝗔𝗚𝗧𝗖 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗦𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻𝘀 𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮’𝘀 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗮𝗻𝗱 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗘𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺 𝘃𝗶𝗮 𝗡𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗦𝘁𝗮𝗸𝗲𝗵𝗼𝗹𝗱𝗲𝗿 𝗘𝗻𝗴𝗮𝗴𝗲𝗺𝗲𝗻𝘁

Thank you to the National Institutes of Health Malaysia (NIH) and the Institute for Medical Research (IMR) for the invitation to the recent Translational Research Stakeholder Engagement Workshop.

The session brought together leaders from research, healthcare, investment and commercialisation to discuss how Malaysian discoveries can progress from the laboratory into real-world healthcare solutions.

Valuable perspectives were shared by Haniza Mohd Anuar, Associate Professor Dr. Caryn Chan Mei Hsien, Dr. Khor Swee Kheng, Navvin Kumar Kirupananandan and Shan Li Tay.

Stronger connections between researchers, clinicians, industry and investors will be essential to transform Malaysia’s scientific talent into impactful innovations with national and global potential.

Strengthening Malaysia’s Translational Research Ecosystem Through Strategic Stakeholder Engagement

29/07/2026

𝗔𝗚𝗧𝗖 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗖𝗼𝗻𝘁𝗿𝗶𝗯𝘂𝘁𝗲𝘀 𝘁𝗼 𝗕𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮’𝘀 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗘𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺 𝗧𝗵𝗿𝗼𝘂𝗴𝗵 𝗘𝗻𝗴𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗕𝗶𝗼𝗲𝗰𝗼𝗻𝗼𝗺𝘆 𝗖𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗠𝗜𝗚𝗛𝗧

Why do many Malaysian technology companies struggle to scale internationally despite having strong talent, science and innovation?

AGTC Genomics recently welcomed representatives from the Malaysian Bioeconomy Development Corporation and the Malaysian Industry-Government Group for High Technology (MIGHT) for an important discussion on strengthening Malaysia’s technology ecosystem and helping local technology companies enter international markets.

Bioeconomy Corporation plays a key role in developing Malaysia’s biotechnology and bio-based industries, including supporting BioNexus Status companies. MIGHT brings together government, industry and strategic partners to advance Malaysia’s high-technology capabilities and future economic opportunities.

During the discussions, AGTC Genomics Founder and CEO, Professor Dr Chee-Onn Leong, shared the company’s journey in advancing precision medicine in Malaysia, as well as its expansion plans across Southeast Asia and the wider Asia-Pacific region.

As a BioNexus Status company and one of Malaysia’s pioneers in genomics, AGTC Genomics has continued to transform scientific innovation into clinically relevant and commercially scalable healthcare solutions.

The visiting teams were particularly impressed by the development and commercialisation of AGTC Genomics’ Malaysian-designed and clinically validated Multi-Cancer Early Detection test.

Using advanced liquid biopsy and ultra-deep sequencing technology, the test is designed to detect molecular signals associated with more than 21 types of cancer through a blood sample.

This achievement demonstrates that Malaysia has the scientific talent, technological capability and commercial potential to develop advanced healthcare solutions that can compete beyond the domestic market.

However, developing technology is only the beginning. Malaysian start-ups also require greater access to growth capital, international partnerships, regulatory support, market access and opportunities to validate their technologies globally.

Malaysia is not short of talent. We are short of opportunities for our talent and technologies to scale.

Malaysian technology companies should not depend solely on the domestic market. They should build with regional and global ambitions from the beginning—developing technologies, products and business models that can compete across Southeast Asia, Asia-Pacific and the world.

AGTC Genomics looks forward to contributing to a stronger, more connected and internationally competitive Malaysian technology ecosystem.

https://www.agtcgenomics.com/post/agtc-genomics-contributes-to-building-malaysia-s-technology-ecosystem-through-engagement-with-bioeco

AGTC Genomics Contributes to Building Malaysia’s Technology Ecosystem Through Engagement with Bioeconomy Corporation and MIGHT

28/07/2026

𝗢𝗻𝗲 𝗧𝗲𝘀𝘁. 𝗠𝗼𝗿𝗲 𝗣𝗼𝘀𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀. 𝗔 𝗖𝗹𝗲𝗮𝗿𝗲𝗿 𝗪𝗮𝘆 𝗙𝗼𝗿𝘄𝗮𝗿𝗱.

For someone newly diagnosed with lung cancer, one question matters most:

“𝗪𝗵𝗶𝗰𝗵 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗶𝘀 𝗺𝗼𝘀𝘁 𝗹𝗶𝗸𝗲𝗹𝘆 𝘁𝗼 𝘄𝗼𝗿𝗸 𝗳𝗼𝗿 𝗺𝗲?”

The answer is not always straightforward.

Lung cancer is not a single disease. Two patients with the same diagnosis may have completely different molecular drivers—and therefore require very different treatment strategies.

Yet when biomarkers are tested one at a time, limited tumour tissue can be exhausted, actionable alterations may be missed, and patients may wait longer for the answers needed to begin treatment.

OncoDx™ Lung Cancer Comprehensive Gene Profiling is designed to simplify that journey.

Using a single FFPE tissue sample, OncoDx™ applies next-generation sequencing to analyse clinically relevant DNA alterations, gene fusions, copy-number changes, TMB and MSI within one integrated assay.

The test evaluates key lung cancer biomarkers, including EGFR, ALK, ROS1, RET, MET, BRAF, KRAS, HER2/ERBB2 and NTRK, helping physicians understand the molecular changes driving each patient’s cancer.

With therapy-matching knowledge covering 109 FDA-approved drugs, OncoDx™ supports companion diagnostic decision-making by translating complex genomic findings into clear, clinically relevant treatment insights.

Because precision oncology is not only about finding a mutation.

It is about understanding what that finding may mean for the patient—while preserving precious tissue, reducing sequential testing and providing actionable results within 7–14 working days.

One patient. One tumour. One comprehensive molecular profile.

A more informed treatment conversation begins with a clearer understanding of the cancer.

📞 Call or WhatsApp: +6012 520 7981
📧 [email protected]
🌐 www.agtcgenomics.com

27/07/2026

𝗟𝗮𝘂𝗻𝗰𝗵𝗶𝗻𝗴 𝗢𝗻𝗰𝗼𝗗𝘅 𝗟𝘂𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗚𝗣: 𝗔 𝗠𝗼𝗿𝗲 𝗜𝗻𝗳𝗼𝗿𝗺𝗲𝗱 𝗣𝗮𝘁𝗵 𝘁𝗼 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁

For many people diagnosed with lung cancer, the first question is:

“Which treatment is most likely to work for me?”

Yet lung cancer is not one single disease. Two patients with the same diagnosis may carry very different molecular changes—and may therefore respond to completely different therapies.

When testing is performed one biomarker at a time, precious tissue may be exhausted, treatment opportunities may be missed, and the patient may wait longer for an answer.

OncoDx™ Lung Cancer Comprehensive Gene Profiling (CGP) changes this journey.

Using one FFPE tissue sample, OncoDx™ applies advanced next-generation sequencing (NGS) to analyse clinically relevant DNA alterations, gene fusions, copy-number changes, TMB and MSI in a single integrated test. The resulting clinician-friendly report connects actionable biomarkers with potential targeted treatment options.

The test evaluates important lung cancer biomarkers—including EGFR, ALK, ROS1, RET, MET, BRAF, KRAS, HER2/ERBB2 and NTRK—helping physicians look beyond the diagnosis and understand the molecular driver behind each patient’s cancer.

With therapy-matching knowledge covering 109 FDA-approved drugs, OncoDx™ Lung Cancer CGP is designed to support companion diagnostic decision-making and help clinicians identify relevant treatment possibilities based on each tumour’s genomic profile.

Because the goal is not simply to find a mutation.

It is to turn that molecular information into a meaningful treatment conversation—while preserving limited tissue, reducing sequential testing and delivering actionable insights within 7–14 working days.

One patient. One tumour. One comprehensive molecular profile.

That is how precision oncology moves from uncertainty towards a more informed treatment strategy.

📞 Call or WhatsApp: +6012 520 7981
📧 [email protected]
🌐 www.agtcgenomics.com

24/07/2026

𝗔𝗚𝗧𝗖 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 & 𝗨𝗠𝗠𝗖 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝗡𝗲𝘅𝘁-𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻, 𝗔𝗳𝗳𝗼𝗿𝗱𝗮𝗯𝗹𝗲 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗳𝗼𝗿 𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮

What if healthcare could become more personal, more precise — and more accessible to everyone?

AGTC Genomics recently had the opportunity to engage with University Malaya Medical Centre (UMMC) to explore the future possibilities of precision and genomic medicine in Malaysia.

Precision medicine is about using a person’s genetic and biological information to better understand disease risk, detect illnesses earlier and help doctors make more informed treatment decisions. Simply put, it is about moving towards the right care, for the right person, at the right time.

Malaysia already has many of the ingredients needed to lead in this field.

🏥 UMMC brings world-class clinical expertise, medical research and healthcare education.

🧬 AGTC Genomics brings advanced genomic technologies, next-generation sequencing and expertise across precision oncology, preventive medicine and personalised healthcare.

As a Malaysian BioNexus Status company, AGTC Genomics has also expanded its reach beyond Malaysia into markets across Southeast Asia and the Asia-Pacific, including Singapore, Hong Kong, South Korea, Vietnam, Thailand and beyond.

This creates exciting possibilities for Malaysia.

Beyond technology, one of the biggest opportunities lies in building our own people and capabilities — training more doctors, scientists, bioinformaticians and healthcare professionals in genomics and precision medicine.

By bringing together the strengths of healthcare, academia, science and industry, Malaysia has the opportunity to build a stronger precision medicine ecosystem — one that is not only advanced, but also affordable, accessible and relevant to our own population.

The future of healthcare is becoming increasingly personalised.

The question is no longer whether precision medicine will transform healthcare.

The question is: Can Malaysia be one of the countries leading that transformation?

At AGTC Genomics, we believe the answer can be yes. 🇲🇾🧬

https://www.agtcgenomics.com/post/agtc-genomics-and-ummc-explore-next-generation-affordable-precision-medicine-for-malaysia

AGTC Genomics and University Malaya Medical Centre Explore Strategic Opportunities to Advance Precision Medicine in Malaysia